Teva Stock Flashes Bearish Signal Once More

TEVA has run up to a trendline with bearish implications in the past

Managing Editor
Oct 17, 2018 at 2:30 PM
facebook twitter linkedin


Drugmaker Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is lower today, down 4.7% to trade at $21.24, amid reports that Express Scripts (ESRX) excluded Teva's migraine drug from coverage. In addition to the drop today, TEVA recently flashed a bearish signal, indicating the slide may be far from over.

Teva stock, for the second time within a month, is within one standard deviation of its 40-day moving average, after a lengthy stretch below this trendline. In the past three years, there have been 11 other signals of this kind, after which Teva shares were down by an average of 4.8% a month later, and positive only 27% of the time, per data from Schaeffer's Senior Quantitative Analyst Rocky White.

Daily Stock Chart TEVA

TEVA's drop today likely snaps a three-day winning streak. Another 4.8% drop in the next month would have the stock breaching the $21 level, which has recently emerged as support the last two months.

There is ample room aboard the bearish bandwagon in the event of a TEVA downturn. Short interest fell by 11% in the most recent reporting period, to 31.8 million shares -- the lowest since July 2017.

The good news for options traders is that TEVA sports a Schaeffer's Volatility Scorecard (SVS) of 93 out of 100, which shows the stock has tended to make larger-than-expected moves on the charts compared to what the options market had priced in. In simpler terms, it may be an opportune time to speculate with Teva options.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners